Alberta’s government this month became the first Canadian province to regulate psychedelic therapy, but the new rules are controversial.
under policy “The state government will regulate the psychedelic drugs psilocybin, psilocin, MDMA, LSD, mescaline, DMT, 5-methoxy-DMT, and ketamine as drugs for the treatment of psychiatric disorders,” it announced on Oct. 5.
“Some of our strongest advocates are first responders and veterans suffering from PTSD and other mental health conditions,” said Mike Ellis, Alberta’s deputy minister for mental health and addiction. said in a statement at the time. As quoted by forbes“As a former police officer myself, I want to make sure that if there are promising practices to make life better for people with these conditions, we are supporting them in a professional way.
On paper, regulation appears to be a breakthrough for psychedelic therapy, which has gained mainstream acceptance in recent years as a potentially effective treatment for many psychiatric and mental health disorders. .
Optimi Health is a Canadian healthcare company specializing in the drug psilocybin. Applause Alberta Government.
“Yesterday, the Alberta government made the bold and politically courageous decision to regulate the use of psychedelic therapy for patients suffering from a variety of treatment-resistant diseases. has received substantial research, including an increasing number of randomized clinical trials emphasizing combining psychotherapy with the “active ingredient of the mushroom” as a novel new approach for the treatment of hosts. On the impact of mental health conditions such as treatment-resistant depression, substance use disorders, and severe anxiety associated with end-of-life diagnoses, said Optimi CEO Bill Ciprick. said in a statement.
“Given the impressive and growing track record of safety in both therapeutic and naturalistic forms, this is a growing body of evidence supporting the benefits of psilocybin-containing mushrooms when used as part of psychotherapy. There is growing international interest in acting quickly to increase patient access to treatment contexts,” Ciprick added.
Ciprick also noted a surge in support for the treatment among leaders in both Canada and the United States.
“We have seen broad bipartisan support for the psilocybin and MDMA bills introduced in state legislatures across the United States. And recently, Honorable Honorable Carolyn Bennett, Canada’s Minister for Mental Health and Addiction, acknowledged that Canada needs a safe drug supply to fight its burgeoning opioid crisis. he said.
“While awaiting further details on Alberta’s regulatory framework, other provincial health ministries have begun to ask the right questions about psychedelic therapy, providing further guidance from the Psychedelic Association of Canada’s Memorandum of Understanding on Regulatory Analysis (MORA), which provides steps – a phased regulatory framework for Canadians at the end of life and in palliative care.”
However, some proponents foresee problems arising from the new regulations.
Nick Kadysh, president of trade group Psychedelics Canada, said the regulation has a lot to do with psychiatrists.
“Any clinic should have a psychiatrist responsible,” he said in a recent interview with the Postmedia. “Any patient should consult a psychiatrist before undergoing these treatments.” We know that wait times for psychiatric services are incredibly long in Alberta, so it becomes an issue of patient access,” Kadish said. As quoted by edmonton journal.
Liam Bedard, coordinator of Psychedelics Canada, agreed.
“Although there are many qualified practitioners who can oversee these treatments, allowing only psychiatrists to administer them bottlenecks access to these potentially very valuable therapeutic tools. “There’s a neck,” he said. according to edmonton journal.